<p>The China National Biotec Group Company (CNBG) has obtained regulatory approval to move a third Covid-19 vaccine candidate into the human testing stage in China, CNBG said on Saturday.</p>.<p>The subsidiary of state-owned China National Pharmaceutical Group (Sinopharm) said that manufacturing the candidate, which is based on protein cultivated in factories, does not require facilities with high biosafety levels.</p>.<p><strong>Also read: <a href="https://www.deccanherald.com/international/uae-china-launch-project-to-produce-sinopharm-vaccine-967719.html" target="_blank">UAE, China launch project to produce Sinopharm vaccine</a></strong></p>.<p>This means it could be easier to produce compared with the two CNBG vaccines already being used in China's mass vaccination drive, which involve active coronavirus during production.</p>.<p>More than ten vaccine candidates led by Chinese scientists have entered different stages of clinical trials.</p>.<p>Four vaccines, two from Sinopharm CNBG, one from Sinovac Biotech and one from CanSino Biologics, have been cleared for use among the general public.</p>.<p>A fifth vaccine from the Institute of Microbiology of the Chinese Academy of Sciences, which is also based on protein, has gained the green light for limited emergency use.</p>
<p>The China National Biotec Group Company (CNBG) has obtained regulatory approval to move a third Covid-19 vaccine candidate into the human testing stage in China, CNBG said on Saturday.</p>.<p>The subsidiary of state-owned China National Pharmaceutical Group (Sinopharm) said that manufacturing the candidate, which is based on protein cultivated in factories, does not require facilities with high biosafety levels.</p>.<p><strong>Also read: <a href="https://www.deccanherald.com/international/uae-china-launch-project-to-produce-sinopharm-vaccine-967719.html" target="_blank">UAE, China launch project to produce Sinopharm vaccine</a></strong></p>.<p>This means it could be easier to produce compared with the two CNBG vaccines already being used in China's mass vaccination drive, which involve active coronavirus during production.</p>.<p>More than ten vaccine candidates led by Chinese scientists have entered different stages of clinical trials.</p>.<p>Four vaccines, two from Sinopharm CNBG, one from Sinovac Biotech and one from CanSino Biologics, have been cleared for use among the general public.</p>.<p>A fifth vaccine from the Institute of Microbiology of the Chinese Academy of Sciences, which is also based on protein, has gained the green light for limited emergency use.</p>